Moreover, the 36-month beta value for ALZN is -0.09. Analysts have varying opinions on the stock, with 1 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for ALZN is 5.19M and currently, short sellers hold a 2.56% of that float. On December 20, 2024, ALZN’s average trading volume was 209.63K shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
ALZN) stock’s latest price update
The stock of Alzamend Neuro Inc (NASDAQ: ALZN) has decreased by -4.80 when compared to last closing price of 1.25. benzinga.com reported 2024-08-19 that Monday, Alzamend Neuro Inc. ALZN stock is trading higher after the company partnered with Massachusetts General Hospital as its contract research organization.
ALZN’s Market Performance
Alzamend Neuro Inc (ALZN) has experienced a 0.00% fall in stock performance for the past week, with a -9.16% drop in the past month, and a -23.23% drop in the past quarter. The volatility ratio for the week is 8.93%, and the volatility levels for the past 30 days are at 6.81% for ALZN. The simple moving average for the last 20 days is -3.60% for ALZN stock, with a simple moving average of -71.23% for the last 200 days.
Analysts’ Opinion of ALZN
Many brokerage firms have already submitted their reports for ALZN stocks, with Ascendiant Capital Markets repeating the rating for ALZN by listing it as a “Buy.” The predicted price for ALZN in the upcoming period, according to Ascendiant Capital Markets is $8 based on the research report published on October 01, 2021 of the previous year 2021.
ALZN Trading at -16.61% from the 50-Day Moving Average
After a stumble in the market that brought ALZN to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -92.10% of loss for the given period.
Volatility was left at 6.81%, however, over the last 30 days, the volatility rate increased by 8.93%, as shares sank -8.46% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -25.62% lower at present.
During the last 5 trading sessions, ALZN remain unchanged, which changed the moving average for the period of 200-days by -88.77% in comparison to the 20-day moving average, which settled at $1.2345. In addition, Alzamend Neuro Inc saw -86.63% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ALZN starting from AULT MILTON C III, who purchase 75 shares at the price of $2.75 back on Aug 06 ’24. After this action, AULT MILTON C III now owns 77,268 shares of Alzamend Neuro Inc, valued at $206 using the latest closing price.
AULT MILTON C III, the Director of Alzamend Neuro Inc, purchase 25 shares at $3.74 during a trade that took place back on Jul 31 ’24, which means that AULT MILTON C III is holding 77,193 shares at $93 based on the most recent closing price.
Stock Fundamentals for ALZN
Current profitability levels for the company are sitting at:
- -76.61 for the present operating margin
- 0.5 for the gross margin
The net margin for Alzamend Neuro Inc stands at -76.86. The total capital return value is set at -1.55. Equity return is now at value -1092.96, with -195.28 for asset returns.
Currently, EBITDA for the company is -9.89 million with net debt to EBITDA at 0.71. When we switch over and look at the enterprise to sales, we see a ratio of 33.31. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.80.
Conclusion
To wrap up, the performance of Alzamend Neuro Inc (ALZN) has been bad in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
